Market Research Report Tumor Necrosis Factor Receptor Superfamily Member | Page 4

Product Description 53
Mechanism Of Action 53
R&D Progress 53
Monoclonal Antibodies to Agonize CD40 and FCGR2B for B-cell Lymphoma and Melanoma - Drug
Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Monoclonal Antibodies to Agonize CD40 for Lymphoma - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Monoclonal Antibody to Agonize CD40 for Oncology - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
RG-7876 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
SEA-CD40 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or
CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Dormant Projects 60
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or
CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Discontinued Products 62
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or
CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Featured News & Press Releases 63
Apr 18, 2016: Seattle Genetics Highlights Data on SEA-CD40 at the American Association for Cancer
Research Annual Meeting 63
Request for Free Sample Report

Apr 13, 2016: Apexigen to Present Data on Its Novel Immuno-Oncology Program APX005M at Upcoming
Cancer Conferences 63
Feb 03, 2016: Fast Forward Pharmaceuticals Initiates Phase II Pilot Studies in Primary Biliary Cirrhosis
and Crohns Disease with anti-CD40 Monoclonal Antibody 64
Nov 17, 2015: Apexigen Presents Positive Data for APX005M in Podium Presentation at Immune
Checkpoint Inhibitors (ICI) Europe 64
Nov 06, 2015: Apexigen Presents Preclinical Data from Novel Immuno-Oncology Candidate APX005M at
SITC 2015 Meeting 65
Jun 16, 2015: Apexigen Doses First Patient in Phase 1 Clinical Trial of Its Immuno-oncology Therapeutic
Antibody APX005M 66